Compare ZURA & IHRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZURA | IHRT |
|---|---|---|
| Founded | 2022 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Broadcasting |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 455.4M | 589.5M |
| IPO Year | 2021 | 2019 |
| Metric | ZURA | IHRT |
|---|---|---|
| Price | $4.51 | $2.39 |
| Analyst Decision | Buy | Sell |
| Analyst Count | 6 | 2 |
| Target Price | ★ $13.00 | $4.25 |
| AVG Volume (30 Days) | ★ 1.8M | 424.8K |
| Earning Date | 05-14-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 54.19 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,864,991,000.00 |
| Revenue This Year | N/A | $9.96 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 0.27 |
| 52 Week Low | $2.01 | $2.32 |
| 52 Week High | $7.25 | $6.56 |
| Indicator | ZURA | IHRT |
|---|---|---|
| Relative Strength Index (RSI) | 33.11 | 32.35 |
| Support Level | $4.36 | N/A |
| Resistance Level | $5.87 | $2.90 |
| Average True Range (ATR) | 0.35 | 0.13 |
| MACD | -0.14 | -0.00 |
| Stochastic Oscillator | 9.71 | 15.52 |
Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.
iHeartMedia Inc is a United States-based audio media company. The company operates through the segments of the Multiplatform Group, the Digital Audio Group, and the Audio & Media Services Group. The company derives prime revenue from the Multiplatform Group segment which includes the company's Broadcast radio, Networks and Sponsorships, and Events businesses. The Digital Audio Group segment includes all of the company's digital businesses, including podcasting; and the Audio & Media Services Group includes Katz Media Group, a full-service media representation business, and RCS Sound Software, a provider of scheduling and broadcast software and services.